Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor. The first-in-human trial of its Freedom system will evaluate a one-year, under-the-skin sensor that links directly with the user’s smartphone, doing away with the need for additional on-body hardware and making a CGM as discreet […]
Senseonics
Beta Bionics insulin patch pump scores FDA clearance
Beta Bionics (NASDAQ: BBNX) has claimed an FDA clearance for its first patch pump insulin delivery system, amid plans to roll out an updated diabetes dosing algorithm and the launch of a new CGM partnership with Senseonics. The three-day, wearable Mint carries a 200-unit insulin reservoir as well as a combination of reusable and disposable […]
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]
Senseonics more than doubles Q2 revenue in post-Ascensia era
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Senseonics, Welldoc partner on next-gen Eversense 365 app development
Senseonics (NYSE:SENS) and Welldoc today announced a strategic partnership to develop a new custom mobile application for Eversense 365. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. The implant […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
Senseonics posts mixed Q1, raises 2026 guidance amid growing Eversense 365 sales
Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
